Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 5/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647917 | 0.88 | POLB (0.53) | CALM1POLBMAOAMAOBDAO | |
| SCHEMBL7518433 | 0.88 | POLB (0.49) | CALM1POLBMAOAMAOBDAO | |
| SCHEMBL4866570 | 0.77 | TSHR (0.54) | POLBMAOAMAOBDAO | |
| SCHEMBL30965432 | 0.72 | HTR1A (0.46) | CALM1CYP19A1 | |
| SCHEMBL15468418 | 0.71 | MAOA (0.39) | CALM1POLBMAOAMAOBDAO | |
| SCHEMBL6521499 | 0.71 | POLB (0.47) | POLBMAOAMAOB | |
| SCHEMBL9609548 | 0.71 | POLB (0.51) | POLBMAOAMAOBDAO | |
| Hydrochloric Acid SCHEMBL11549616 | 0.69 | CALM1 (0.38) | CALM1POLBMAOAMAOBDAO | |
| SCHEMBL981029 | 0.69 | CALM1 (0.42) | CALM1MAOAMAOBDAOPTPN1 | |
| SCHEMBL110859 | 0.69 | CALM1 (0.52) | CALM1DAOLTA4HIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6384031-B1 | — | — | None | — | — | US | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-08-22 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | BUCHWALD STEPHEN L (US) | 2005-03-24 | — | — | US | disclosed |
| US-6787655-B2 | TRANSITION-METAL-CATALYZED ASYMMETRIC 1,4-ADDITION OF A NUCLEOPHILE, E.G., HYDRIDE, TO CYCLIC AND ACYCLIC ENOATES AND ENONES AND THE CATALYST CONTAINING A COPPER AND AN ASYMMETRIC BIDENTATE BISPHOSPHINE LIGAND | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-09-07 | — | — | US | disclosed |
| US-6667309-B2 | Such as 3-benzyl-2-cyclopenten-1-one; for treatment of gastrointestinal disorders such as irritable bowel syndrome or esophageal reflux, and inhibiting side effects with administration of erythromycin | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-03 | — | — | US | disclosed |
| US-6465664-B1 | CATALYZED WITH A TRANSITION METAL CATALYST COMPOSED OF A COPPER COMPOUND AND AN ASYMMETRIC LIGAND, SUCH AS A PHOSPHINE, A NUCLEOPHILE AND A BASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-10-15 | — | — | US | disclosed |
| US-20020103238-A1 | Novel cyclobutene derivatives useful as antagonists of the motilin receptor | CHEN ROBERT H (US) | 2002-08-01 | — | — | US | disclosed |
| US-6384031-B2 | SUBSTITUTED PHENYLAMINO(METHYLCYCLOBUTENE) DERIVATIVES ARE USEFUL IN TREATING GASTROINTESTINAL DISORDERS ASSOCIATED WITH ANTAGONIZING THE THE MOTILLIN RECEPTOR | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-07 | — | — | US | disclosed |
| US-20010056106-A1 | Novel cyclobutene derivatives useful as antagonists of the motilin receptor | DAMASIO JR, JOSPEH | 2001-12-27 | — | — | US | disclosed |
| WO-2001068622-A1 | NOVEL CYCLOBUTENE DERIVATIVES USEFUL AS ANTAGONISTS OF THE MOTILIN RECEPTOR | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001019761-A2 | ASYMMETRIC 1,4-REDUCTIONS OF AND 1,4-ADDITIONS TO ENOATES AND RELATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | CALM1 3576/4885POLB 2479/4885MAOA 2486/4885 |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | CALM1 3544/4885POLB 3022/4885MAOA 758/4885 |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, NQO1, CBR3 | CALM1 3344/4885POLB 2049/4885MAOA 437/4885 |
| US-20020103238-A1 | Novel cyclobutene derivatives useful as antagonists of the motilin receptor | MLNR, GIPR, CCKBR | CALM1 2327/4885POLB 2278/4885MAOA 2200/4885 |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | CALM1 3576/4885POLB 2479/4885MAOA 2486/4885 |
| US-20010056106-A1 | Novel cyclobutene derivatives useful as antagonists of the motilin receptor | MLNR, GIPR, CCKBR | CALM1 2327/4885POLB 2278/4885MAOA 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.